Serotonin-dopamine antagonist

0 marketed 2 in Phase 3

This page covers all Serotonin-dopamine antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-HT2A receptor, D2 receptor.

Targets

5-HT2A receptor, D2 receptor

Phase 3 pipeline (2)

Lumateperone low dose · Intra-Cellular Therapies, Inc. · Psychiatry
Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.
Lumateperone (ITI-007) · Intra-Cellular Therapies, Inc. · Psychiatry
Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.